The P-III clinical trial evaluates the safety & efficacy of ReGenTree’s (joint venture between RegeneRx Biopharmaceuticals & HLB Therapeutics) RGN-259 eyedrops (n=10) vs PBO (n=8) in patients with Neurotrophic Keratopathy (NK)
The results from the study demonstrated healing of persistent epithelial defects in patients with Stages 2 & 3 NK along with statistically significant healing at day 43. The efficacy data depicted complete healing after 4wks. in 6 of 10 vs 1 of 8 patients
RGN-259 is a sterile preservative-free, eye drop which reduces damage & improves healing for the treatment of ophthalmic indications incl. dry eye syndrome & neurotrophic keratopathy
Ref: PRNewswire | Image: RegeneRx
Related News:- Novartis Announces Spin-Off of Alcon Eye Care Business on April 9- 2019
